Antibody-based Proteomics: From bench to bedside

Area of Science:

• Immunology
• Proteomics
• Biotechnology

Background:

• Antibodies have transitioned from disease biomarkers to potent therapeutic agents over 75 years.
• The identification of monoclonal antibodies (mAbs) and advancements in immunological tools have accelerated this evolution.
• Antibody-based proteomics offers a powerful approach to analyze cellular and tissue proteomes.

Purpose of the Study:

• To review the application of antibodies in assessing cellular and tissue proteomes.
• To discuss the integration of large-scale datasets with clinical data for marker identification.
• To compare antibody production methodologies and validation tools for clinical relevance.

Main Methods:

• Integration of high-throughput proteomics and transcriptomics data with literature and clinical data.
• Literature review and expert experience to compare in vivo and in vitro antibody production techniques.
• Description of available validation tools for antibody-based approaches.

Main Results:

• Antibody-based proteomics requires specific analytical and technological pipelines.
• Methodologies for producing specific antibodies (in vivo and in vitro) have been compared.
• Validation tools and the use of molecular signatures for clinical applications are presented.

Conclusions:

• Antibodies are crucial tools for proteomic assessment with significant clinical potential.
• Effective antibody development and validation are essential for translating research findings to clinical practice.
• Antibody-based molecular signatures are emerging for both research and clinical settings.